CClinicalTrials.gg
CompletedNCT017102025-HTTLPRUpdated Mar 20, 2015

Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration

An observational study in Major Depressive Disorder and Anxiety Disorders, sponsored by University of Texas at Austin. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-20.

Sponsored by University of Texas at Austin · Observational

Study type
Observational
Model
Case-control
Enrollment
120
Ages
18 Years and older
Sex
All
01

Study summary

The current study will test the causal relationship between elevated levels of cortisol and the serotonin transporter gene (5-HTTLPR) as these factors influence sensitivity to environmental threat. The investigators predict that carriers of the short allele of the serotonin transporter gene who have elevated cortisol levels will be most sensitive to threatening environments, whereas carriers of the long allele who do not have elevated cortisol (placebo subjects) will be least sensitive.

Read the detailed description

Depression vulnerability has been linked to certain variants of the serotonin transporter gene. Research indicates that a polymorphism of the serotonin transporter (5-HTTLPR) gene appears to moderate the association between life stress and depression onset. Life stress robustly predicts depression onset for individuals with two short 5-HTTLPR alleles. Individuals homozygous for the short 5-HTTLPR allele thus appear to be more sensitive to the effect of life stress, which in turn contributes to depression onset. A recent study showed that short allele carriers presented with a threat (social or other threats) who also had high levels of testosterone had elevated cortisol after exposure to the threat. There is neurobiological evidence that short allele status, elevated testosterone levels, and elevated cortisol levels are all linked to amygdala hyper-reactivity to the same classes of environmental threats. Thus, this study will test, for the first time, a potential interaction between 5-HTTLPR status and experimentally manipulated cortisol levels as risk factors for downstream mood and/or anxiety disorders by examining potential dysregulated stress responses among short allele carriers who have elevated cortisol levels.

02

Conditions studied

  • Major Depressive Disorder
  • Anxiety Disorders

Keywords

  • Hydrocortisone
  • Cortisol
  • Testosterone
  • Stress
  • Serotonin
  • 5-HTTLPR
  • Amygdala
  • Depression
03

In context

Depressive Disorder

4,845 studies on the registry are indexed under Depressive Disorder; 514 are open to participants now.

This study's enrollment of 120 is below the median of 150 across 653 observational studies indexed under Depressive Disorder.

Browse Depressive Disorder studies →

Lead sponsor

University of Texas at Austin is the lead sponsor of 319 studies on the registry; 78 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

University of Texas at Austin students

Inclusion criteria

  • None

Exclusion criteria

Exclusion Criteria:

  • Are you under the age of 18 years old?
  • Have you ever had an allergic reaction to hydrocortisone?
  • Do you have diabetes or high blood pressure?
  • Do you have any thyroid, liver, heart, lung, or kidney problems?
  • Do you have herpes, HIV or any sexual transmitted disease?
  • Are you currently pregnant or think you might be pregnant? Have you taken RU486, Plan B or "Morning After Pill" within the last 2 weeks? - Are you currently breastfeeding?
  • Have you been sick within the last week? Do you have any fungal infections?
  • Have you been exposed to measles or chicken pox in the last week?
  • Have you ever had a seizure?
  • Do you have any disease of bony tissue, such as osteoporosis?
  • Do you have any autoimmune diseases, such as myasthenia gravis?
  • Do you have multiple sclerosis?
  • Do you have any condition that compromises you immune system function or causes you to be more likely to get sick?
  • Have you had any recent surgeries?
  • Do you have and gastrointestinal problems, such as ulcers, diverticulitis, colitis, hepatitis, or Crohn disease?
  • Are you taking any of the following medications: nevirapine, telbivudine, sipuleucel-T (IV), natalizumab (IV)?
  • Have you received any vaccinations within the last week?
  • With the exception of vitamins, have you taken any medications in the last 3 days, including all over-the counter medications and/or supplements (e,g. Tylenol, ibuprofen, St. John's Wort, cold remedies)?
  • Do you currently have or have you had in the past of any kind of cancer?
  • Do you have any significant medical or psychiatric illnesses not listed above?
05

Study design

Observational model
Case-control
Enrollment
120 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Placebo

    Control group who will not receive hydrocortisone. Will act as a comparison group to the hydrocortisone group.

  • Experimental: Hydrocortisone

    Group will receive 20mg oral hydrocortisone

    Drug: Hydrocortisone

Interventions

  • DrugHydrocortisone

    Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.

    Also known as: Cortef, Cortisol, Hydrocortone

06

What researchers measure

Primary outcomes

  1. Change in testosterone concentration

    Subjects will be administered hydrocortisone or placebo. One hour after administration, they will be exposed to an environmental threat manipulation. 20 minutes after this manipulation, saliva will be collected, and testosterone concentrations will be assessed and compared to pre-manipulation concentrations

    Time frame: 2 hours post hydrocortisone administration

07

Study locations

2 sites
  • University of Texas at Austin Department of Psychology
    Austin, Texas 78712, United States
  • University of Texas at Austin
    Austin, Texas 78712, United States
08

References and documents

Publications

  • Josephs RA, Telch MJ, Hixon JG, Evans JJ, Lee H, Knopik VS, McGeary JE, Hariri AR, Beevers CG. Genetic and hormonal sensitivity to threat: testing a serotonin transporter genotype x testosterone interaction. Psychoneuroendocrinology. 2012 Jun;37(6):752-61. doi: 10.1016/j.psyneuen.2011.09.006. Epub 2011 Oct 5. PubMed 21978869 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01710202
Lead sponsor
University of Texas at Austin
Responsible party
Sponsor
First posted
Oct 19, 2012
Start date
Oct 2012
Primary completion
Dec 2013
Completion
Nov 2014
Last update
Mar 20, 2015

Study contacts

Robert A Josephs, Ph.D.
principal investigator · University of Texas at Austin

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion